HedgeChatter

  • Home /
  • Tag Archives

action

Trapped. Why can't stock market break out? – CNBC.com

Please choose a subscription
Breaking News
CNBC’s latest news headlines
Morning Squawk
Daily before the bell news roundup
Evening Brief
Daily recap of the day’s top headlines
Guest Alerts
Guest information & reminders for your calendar
Your Wealth
Weekly advice on managing your money
Options Action
Insight from the Options Action panelJob IndustryAdvertising/MarketingAutomotiveCommunications/PRConstruction/ManufacturingEducationFinance/Banking/InsuranceLegalMedia/EntertainmentMedical/Health CareMining/Oil/Gas/UtilitiesGov’t/Non-ProfitReal EstateRetailTechnology/ITTransportation/ShippingTravel/HospitalityOther

This article: 

Trapped. Why can't stock market break out? – CNBC.com
 […]

May 14, 2015 Byunknown , , , , , , , , , , Comments Off on Trapped. Why can't stock market break out? – CNBC.com read more

The Trend is Your Friend… Until it Stabs You in the Back

The trend is your friend…You’ve heard that one before. Everyone has. Why is it so famous?Simple: Markets trend. Period. It doesn’t matter if you’re a value investor, daytrader, swing trader, or stargazer– you can’t deny this simple truth.Today I’m going to show you how you can use a trending market to your advantage—but also what to do when the trend […]

May 11, 2015 ByGreg Guenthner , , , , , , , , Comments Off on The Trend is Your Friend… Until it Stabs You in the Back read more

Oppenheimer Comments On 2 Biotech Stocks – Centene … – Benzinga

Related CNCOppenheimer Boosting Targets In Healthcare On ‘Exposure To Interest Rate Changes’8 Managed Care Stocks To Watch In Earnings Season’Non-Cyclical Consumer Healthcare’: How This Sector Will Create Long-Term Wealth(Seeking Alpha)Related Biotech: Anatomy Of An Investing Mania?Bind Therapeutics Rallies Off Oppenheimer RatingIn separate reports, Oppenheimer analysts commented on the pipelines of two Biotech majors – Centene Corp (NYSE: CNC) and BIND […]

April 27, 2015 ByMonica Gerson , , , , , , , , , , , Comments Off on Oppenheimer Comments On 2 Biotech Stocks – Centene … – Benzinga read more

Oppenheimer Comments On 2 Biotech Stocks – Benzinga

Related CNCOppenheimer Boosting Targets In Healthcare On ‘Exposure To Interest Rate Changes’8 Managed Care Stocks To Watch In Earnings Season’Non-Cyclical Consumer Healthcare’: How This Sector Will Create Long-Term Wealth(Seeking Alpha)Related Biotech: Anatomy Of An Investing Mania?Bind Therapeutics Rallies Off Oppenheimer RatingIn separate reports, Oppenheimer analysts commented on the pipelines of two Biotech majors – Centene Corp (NYSE: CNC) and BIND […]

April 27, 2015 ByMonica Gerson , , , , , , , , , Comments Off on Oppenheimer Comments On 2 Biotech Stocks – Benzinga read more

2 Biotech Stocks Deutsche Bank Just Initiated – Sagent … – Benzinga

Related SGNT5 NASDAQ Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 YearsPorat To Google Just One Of The Week’s Top Management Changes; Here Are 7 MoreRelated IPXLFTC Requires Divestitures in Connection With Impax Laboratories Inc.’s Proposed Acquisition of CorePharma, LLCJPM Securities Picks Through Biotech News For WinnersMylan makes $205/share bid for Perrigo; Generic firms rally(Seeking Alpha)Shares of […]

April 8, 2015 ByJavier Hasse , , , , , , , Comments Off on 2 Biotech Stocks Deutsche Bank Just Initiated – Sagent … – Benzinga read more

2 Biotech Stocks Deutsche Bank Just Initiated

Shares of Sagent Pharmaceuticals Inc (NASDAQ: SGNT) and Impax Laboratories Inc (NASDAQ: IPXL) were up on Wednesday, after analysts at Deutsche Bank initiated coverage on Tuesday.
Sagent Pharmaceuticals
The analysts initiated coverage of Sagent with a Buy rating and a $29 price target. They say they have always liked the biotech company’s “focus on the attractive generic injectables segment but now believe […]

April 8, 2015 , , , , , , , Comments Off on 2 Biotech Stocks Deutsche Bank Just Initiated read more

Volatility defines the stock market

It was a tumultuous week. Investors should get used to it because volatility is going to be with us for some time to come. You can blame a lot of things, but the evidence suggests that the dollar is the main culprit behind the market’s gyrations.The rate of ascent, rather than the direction of the dollar, is largely to blame […]

March 27, 2015 ByBill Schmick , , , , , , , , , , , Comments Off on Volatility defines the stock market read more

Watch out for market correction, experts say – CNBC.com

Wednesday’s stock decline looked like end-of-quarter kind of action, said Jack Bouroudjian, chief investment officer of Index Financial Partners. However, he thinks the real question is what will happen at the beginning of the next quarter.”One of the things that worries me is that we’re entering a very difficult time for stocks,” he told “Closing Bell.”Read More Stocks plunge, but […]

March 25, 2015 Byunknown , , , , , , , , , , Comments Off on Watch out for market correction, experts say – CNBC.com read more

Maxim Sees Major Upside In These Biotech Stocks

In a recent report, analysts at Maxim Group discussed the biotechnology sector and gave their outlook for five names in the space. Here’s a rundown of what they had to say.Athersys, Inc. (NASDAQ: ATHX)Analysts believe that Athersys may have found a “sweet spot” for stroke treatment timing, as data from a phase II trial of MultiStem treatment one to two […]

March 14, 2015 , , , , , , , , , Comments Off on Maxim Sees Major Upside In These Biotech Stocks read more

Maxim Sees Major Upside In These Biotech Stocks – Athersys, Inc …

Related ATHXMorning Market GainersWhy Investors Are Watching Athersys Ahead Of Stem Cell DataIn a recent report, analysts at Maxim Group discussed the biotechnology sector and gave their outlook for five names in the space. Here’s a rundown of what they had to say.Athersys, Inc. (NASDAQ: ATHX)Analysts believe that Athersys may have found a “sweet spot” for stroke treatment timing, as […]

March 14, 2015 ByWayne Duggan , , , , , , , , , , Comments Off on Maxim Sees Major Upside In These Biotech Stocks – Athersys, Inc … read more